Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Gains from Investment Securities: 2022-2024

Historic Gains from Investment Securities for Gossamer Bio (GOSS) over the last 1 years, with Dec 2024 value amounting to $52,000.

  • Gossamer Bio's Gains from Investment Securities was N/A to $52,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $4.6 million, marking a year-over-year change of. This contributed to the annual value of $5.3 million for FY2024, which is 829.75% up from last year.
  • As of Q4 2024, Gossamer Bio's Gains from Investment Securities stood at $52,000, which was down 99.07% from $5.6 million recorded in Q3 2024.
  • Over the past 5 years, Gossamer Bio's Gains from Investment Securities peaked at $5.6 million during Q3 2024, and registered a low of -$726,000 during Q3 2023.
  • Over the past 3 years, Gossamer Bio's median Gains from Investment Securities value was $52,000 (recorded in 2024), while the average stood at $1.5 million.
  • Data for Gossamer Bio's Gains from Investment Securities shows a peak YoY skyrocketed of 866.12% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Gossamer Bio's Gains from Investment Securities stood at $3.0 million in 2022, then reached -$726,000 in 2023, then skyrocketed by 866.12% to $52,000 in 2024.
  • Its Gains from Investment Securities was $52,000 in Q4 2024, compared to $5.6 million in Q3 2024 and -$316,000 in Q1 2024.